Hypoglycemic Effect Using Ayurveda Treatment Of Sodhan And Shaman Therapy For The Management Of Madhumeha(Obese Diabetic).

Phase 4

• Conditions: Health Condition 1: E119- Type 2 diabetes mellitus without complications

• Registration Number: CTRI/2022/09/046014
• Lead Sponsor: ALL INDIA INSTITUTE OF AYURVEDA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Patients of either gender in the age group of 30-60 years.

2.Patients with classical signs and symptoms of Madhumeha.

3.Patients giving the clinical history of Obese Diabetic (DM Type II).

4.Patients with random blood sugar level (RBS) >200 mg/dl up to 350 mg/dl

5.Fasting blood sugar (FBS) >126 mg/dl up to 250 mg/dl

6.Postprandial blood sugar (PPBS) >140 mg/dl up to 350 mg/dl

7.Glycosylated haemoglobin > 7.5% up to 15%

NOTE (In the above-given criteria, there is one should be present and raised HbA1C is necessary.)

8.Sthula Pramehi (Overweight / Obese - BMI >25 g/m2)

9.Newly /early diagnosed cases to be included as per following criteria:

i.Patients who are not taking any conventional medicine for more than 3 months, whose sugar levels are raised and fall within the inclusive criteria mentioned above and are willing to take Ayurvedic treatment.

ii.Patient accidently diagnosed in routine check-up or when appeared with other complaints in the hospital.

iii.Early diagnosed diabetic patients (Maximum 3 years of diabetic history) and not taking any pharmacological drugs since last 3 months.

Exclusion Criteria

1.Patients having insulin dependent DM (type 1) and receiving insulin / OHA

2.Excessive blood glucose: FBS > 250 mg/dl, PPBS > 350 mg/dl, RBS >350 mg/dl and HbA1c >15%

3.Emergency conditions in cases of DM.

4.Patients with acute/chronic liver disease with elevated liver enzymes.

5.Chronic complications like microvascular and macrovascular derangements.

6.Patients reporting to be hypersensitive to any of the proposed trial drugs.

7.Pregnant women/ lactating mothers

8.Participation in other clinical studies in past 12 weeks.

9.Takes psychotropic medications that raise blood glucose (e.g. atypical antipsychotics)

Study & Design

• Study Type: Interventional
• Study Design: Not specified